NEW YORK, April 7, 2016 /PRNewswire/ -- Cancer is the number two cause of death, behind only cardiovascular disease. The most common types of cancer worldwide include breast cancer, colorectal cancer, lung cancer, and prostate cancer. For these and other types of cancer, novel biomarkers, therapies, and diagnostic tests are being developed. Cancer Markers provides market assessment, estimate and competitive analysis for tests for oncology that use biomarkers. This includes a range of technologies made by scores of companies. The report contains products designed to determine risk for cancer, screen for cancer, test for cancer, aid in prognosis and personalize therapy. Among the technologies are the following:
Histology/Cytology:
Immunohistochemistry
In situ hybridization
Immunoassays - Tumor Markers:
Flow Cytometry
Rapid Tests:
Molecular Marker-Based
Estimates for these segments are provided for 2015 and 2020. In addition, some specific marker breakouts are provided along with significant detail of products on the market. This report reviews the progression of cancer diagnostic technologies over the past 10-15 years and notes some trends in test strategies as well.
Cancer Markers provides the following data:
Worldwide Cancer Biomarkers Diagnostic Market - 2015 and 2020 (IHC, ISH, Immunoassays, Flow, Rapid, Molecular)
Selected International Agreements
Worldwide Cancer Biomarkers Diagnostic Market Percentage (IHC, ISH, Flow Cytometry, Molecular-Based Assays, NMP22, FOB, PSA, CEA, CA125, AFP, Other Tumor Markers)
Estimated Global Incidence and Mortality due to Cancer, 2012 - By Regions of the World
Selected Widely Used Tumor Markers
Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels for Cancer Screening, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels to Predict Prognosis of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels to Predict Response to Therapy, and Companies Developing/Marketing These Biomarkers
Selected FDA Cleared/Approved Companion Diagnostic Tests, and Companies Developing/Marketing These Biomarkers
Selected Companies Developing/Marketing Cancer Tests
Common Next Generation Molecular Test Traits
Selected Sample Preparation Reagents
Selected Cancer Test Innovations, 2015
This report contains company profiles, including coverage of the following:
Abbott Laboratories
Alere Inc. (Abbott)
bioMerieux SA
Hologic, Inc.
Illumina, Inc.
QIAGEN N.V.
Roche
Thermo Fisher Scientific, Inc.
The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.
Read the full report: http://www.reportlinker.com/p03756528-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article